Alnylam Provides Clinical, Financial Goals for 2010, Reiterates Previous Guidance

Among Alnylam's goals for the year are forging at least four industry alliances and ending the year with more than $325 million in cash.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.